LUMICELL, INC.

NEWTON, MA · Founded 2008 · Medtech · Private

Intraoperative fluorescence imaging system with activatable molecular imaging agent and hand-held imaging device for real-time cancer margin detection during breast surgery

Claim this profile

Follows are private to you and power your alerts

Updated · lumicell.com

Sector
Medtech
Headquarters
NEWTON, MA
Founded
2008
Latest Form D
$198M, May 2025
Total capital
$333M
Federal grants
$2M
2 awards · 2016–2017
Rank in peer group#60 of 477
Private capital raised
$331M
9 Form D · last May 2025
18 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
5
19 pending · first 2019
Rank in peer group#57 of 477

Capital timeline

20112013201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $333M$1M$937K3rd Form D$6.8M5th Form D$20.4M6th Form D$75.8M
2011201520192023FEDERAL ↑EQUITY ↓Cumulative $333M$1M$937K6th Form D$75.8M

Latest events

  • Private capital raisedForm D · SEC · 9th filing$198M
  • Private capital raisedForm D · SEC · 8th filing$2.7M
  • Private capital raisedForm D · SEC · 7th filing$2.3M
  • Private capital raisedForm D · SEC · 6th filing$75.8M
  • Private capital raisedForm D · SEC · 5th filing$20.4M
  • Private capital raisedForm D · SEC · 4th filing$20.7M
  • Federal grantHealth and Human S · Phase II · A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery$937K
  • Private capital raisedForm D · SEC · 3rd filing$6.8M
  • Private capital raisedForm D · SEC · 2nd filing$1M
  • Private capital raisedForm D · SEC · 1st filing$2.7M
Show 1 earlier federal award
  • Federal grantHealth and Human S · Phase II · A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 477 peers

Line = median

Medtech · Device

  • Federal grants#60 · top 13%
  • Granted patents#57 · top 12%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Andrey J. ZarurDirectorNamed in SEC Form D filings
  • Carlos J. GonzalezDirectorNamed in SEC Form D filings
  • Cosimo FiorenzaDirectorNamed in SEC Form D filings
  • David David FurneauxDirectorNamed in SEC Form D filings
  • Elon BomsDirectorNamed in SEC Form D filings
  • Howard HechlerExecutive Officer, DirectorNamed in SEC Form D filings
Show all 17 people
  • James J. AlecxihDirectorNamed in SEC Form D filings
  • JAMES DAVID SCHUERMANNDirectorNamed in SEC Form D filings
  • Jorge FerrerExecutive OfficerNamed in SEC Form D filings
  • KELLY DAVID LONDYExecutive Officer, DirectorNamed in SEC Form D filings
  • Kevin David HershbergerExecutive OfficerNamed in SEC Form D filings
  • KEVIN DAVID KRENITSKYDirectorNamed in SEC Form D filings
  • Michael David RuettgersDirectorNamed in SEC Form D filings
  • Mike RuettgersDirectorNamed in SEC Form D filings
  • Moungi David BawendiDirectorNamed in SEC Form D filings
  • RALPH DAVID WEISSLEDERDirectorNamed in SEC Form D filings
  • W. David LeeExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 5 granted of 24
  • PendingMedical Imaging Device And Methods Of UseUSPTOApplication 19202650
  • PendingSystem And Method For Residual Cancer Cell DetectionUSPTOApplication 18360069
  • PendingSystem And Method For Thresholding For Residual Cancer Cell DetectionUSPTOApplication 18366003
Show all 24 patent records
  • Medical Imaging Device And Methods Of UseJan 22, 2026 · Application 19202650Pending
  • System And Method For Residual Cancer Cell DetectionJan 18, 2024 · Application 18360069Pending
  • System And Method For Thresholding For Residual Cancer Cell DetectionDec 14, 2023 · Application 18366003Pending
  • System And Method For Thresholding For Residual Cancer Cell DetectionOct 24, 2023 · US 11,793,594Granted
  • System And Method For Residual Cancer Cell DetectionOct 3, 2023 · US 11,771,324Granted
  • Methods And Systems For Spatially Identifying Abnormal CellsJul 20, 2023 · Application 18158427Pending
  • Sterile Barrier For Medical Imaging DeviceMay 4, 2023 · Application 17977215Pending
  • Sealed Imaging DevicesMay 4, 2023 · Application 17977179Pending
  • Optical Fiber Fixtures For Imaging DevicesMay 4, 2023 · Application 17977241Pending
  • Calibration Tip For Imaging DevicesMay 4, 2023 · Application 17977243Pending
  • Methods And Systems For Spatially Identifying Abnormal CellsFeb 28, 2023 · US 11,592,396Granted
  • Medical Imaging Device And Methods Of UseFeb 23, 2023 · Application 17901649Pending
  • Methods And System For Image Guided Cell AblationSep 20, 2022 · US 11,446,088Granted
  • Methods And System For Image Guided Cell Ablation With Microscopic ResolutionMay 14, 2019 · US 10,285,759Granted
  • Sealed Imaging DevicesApplication 63275855Pending
  • Sterile Barrier For Medical Imaging DeviceApplication 63275869Pending
  • Optical Fiber Fixtures For Imaging DevicesApplication 63275728Pending
  • Calibration Tip For Imaging DevicesApplication 63275679Pending
  • Sterile Barrier For Medical Imaging DeviceApplication PCTUS2022048362Pending
  • Optical Fiber Fixtures For Imaging DevicesApplication PCTUS2022048369Pending
  • System And Method For Thresholding For Residual Cancer Cell DetectionApplication PCTUS2019065319Pending
  • System And Method For Thresholding For Residual Cancer Cell DetectionApplication 62786657Pending
  • Sealed Imaging DevicesApplication PCTUS2022048367Pending
  • Calibration Tip For Imaging DevicesApplication PCTUS2022048363Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .